<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545165</url>
  </required_header>
  <id_info>
    <org_study_id>1802018988</org_study_id>
    <nct_id>NCT03545165</nct_id>
  </id_info>
  <brief_title>177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC</brief_title>
  <official_title>Phase I/II Dose-Escalation Trial of Combination Fractionated-dose 177Lu-J591 and 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I dose escalation study with combination of 177Lu-J591 and 177Lu-PSMA-617 using a&#xD;
      dose-fractionated regimen will be performed in patients with documented progressive&#xD;
      metastatic CRPC. The cumulative 177Lu-J591 dose for each subject will be 2.7 GBq/m2 (73&#xD;
      mCi/m2) of 177Lu with 20 mg J591 and the cumulative 177Lu-PSMA-617 dose for each subject will&#xD;
      vary (depending on the Cohort) from 3.7 GBq (100 mCi) to 18.5 GBq (500 mCi). The&#xD;
      177Lu-PSMA-617 dose will be escalated in up to 6 different dose levels (3+3 dose-escalation&#xD;
      study / de-escalation design). For the phase II portion, a minimum number of 14 patients will&#xD;
      be enrolled at MTD (including those enrolled at MTD in Phase I) and a maximum of 24.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single-center Phase I dose-escalation study designed to determine the&#xD;
      dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of combination of&#xD;
      177Lu-J591 and 177Lu-PSMA-617 in a two-week dose-fractionation regimen. 177Lu-J591 will be&#xD;
      given at a moderate dose previously demonstrated to be safe x2 infusions two weeks apart. For&#xD;
      177Lu-PSMA-617 the dose escalation will start at 3.7 GBq (100 mCi) and escalate in increments&#xD;
      of 1.85 GBq (50 mCi) for each dose to a planned maximum of 9.25 GBq (250 mCi) x2 doses, 2&#xD;
      weeks apart. Should there be unacceptable toxicity at the initial dose level, we will&#xD;
      de-escalate to dose level -1 (1.85 GBq / 50 mCi per dose). After the phase I study has&#xD;
      established a MTD, the Phase II, single-arm trial will start.&#xD;
&#xD;
      Patients must have documented progressive metastatic CRPC disease based on Prostate Cancer&#xD;
      Working Group 3 (PCWG3) criteria in order to be eligible for enrollment. Upon meeting the&#xD;
      inclusion and exclusion criteria and signing the informed consent and HIPPA form, subjects&#xD;
      will undergo the screening. As part of the screening, subjects will get a single dose of&#xD;
      68Ga-PSMA-HBED-CC and will have a PET/CT. Nuclear Medicine physician(s) will review the&#xD;
      PET/CT scans to document PSMA expression at tumor site(s).&#xD;
&#xD;
      Subjects will have Lutetium-177 Planar/SPECT Imaging on Day 8 (±1 day) after the first dose&#xD;
      of 177Lu-J591 + 177Lu-PSMA-617. Optimal images will be performed on selected consenting&#xD;
      subjects between the initial treatment visit #1 on Day 1 and Day 4 and prior to treatment&#xD;
      visit #2 on D15 ±1. Subjects will be closely monitored for AEs (weekly x2 weeks, then every 2&#xD;
      weeks for one month, at 8 and 12 weeks, and then every 4 weeks for next 3 months).&#xD;
&#xD;
      Upon completion of investigational treatment with dose-fractionation regimen of the&#xD;
      combination of 177Lu-J591 + 177Lu-PSMA-617, subjects will undergo 68Ga-PSMA-HBED-CC injection&#xD;
      and same day PET/CT at the end of study visit to document treatment response. Subsequently&#xD;
      survival data and additional treatment(s) information will be captured from their routine&#xD;
      Standard of care (SOC) visits.&#xD;
&#xD;
      .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor withdrawal&#xD;
  </why_stopped>
  <start_date type="Actual">April 18, 2018</start_date>
  <completion_date type="Actual">July 15, 2020</completion_date>
  <primary_completion_date type="Actual">July 15, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Dose Limiting Toxicity (DLT) of Combination Therapy in a 2-Week Dose-Fractionation Regimen</measure>
    <time_frame>Approximately 3 months after enrollment</time_frame>
    <description>Dose limiting toxicity of combination therapy was determined by monitoring for adverse events following therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RP2D) of Combination Therapy in a 2-Week Dose-Fractionation Regimen</measure>
    <time_frame>Approximately 3 months after enrollment</time_frame>
    <description>Cumulative maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of combination therapy was determined by monitoring dose-limiting toxicity and adverse events in the dosing or treatment cohorts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Proportion With PSA Decline Following the Dose-Fractionated Combination Therapy by Comparing the Change in PSA Levels After Therapy to the Baseline, Pre-Treatment PSA.</measure>
    <time_frame>At baseline and at 2 weeks on therapy</time_frame>
    <description>The proportion of patients with PSA decline following treatment with the combination of 177Lu-J591 and 177Lu-PSMA-617 was determined by comparing PSA levels prior to and following radionuclide therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Radiographic Response by RECIST 1.1 With Prostate Cancer Working Group 3 (PCWG3) Modifications</measure>
    <time_frame>At the efficacy (scan) visit time point (12 weeks)</time_frame>
    <description>Radiographic response rate was determined by scoring follow-up scans after therapy; RECIST 1.1 criteria with PCWG3 modifications were utilized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Progression-Free Survival by PCWG3 Criteria</measure>
    <time_frame>Through study completion, up to 26 months</time_frame>
    <description>Biochemical progression-free survival was determined from date of first therapy to date of progression by PSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Progression-Free Survival by PCWG3 Criteria</measure>
    <time_frame>Through study completion, up to 26 months</time_frame>
    <description>Radiographic progression-free survival was determined from date of first treatment to date of progression on follow-up imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Following Treatment With the Combination of 177Lu-J591 and 177Lu-PSMA-617 in a 2-Week Dose-Fractionation Regimen</measure>
    <time_frame>Through study completion, up to 26 months</time_frame>
    <description>Overall survival following treatment with the combination of 177Lu-J591 and 177Lu-PSMA-617 was determined from date of first treatment to date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CTC Count as Measured by CellSearch</measure>
    <time_frame>At the efficacy (scan) visit time point (12 weeks)</time_frame>
    <description>Patients' circulating tumor cell counts were obtained prior to and following therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Favorable CTC Count as Measured by Cell Search</measure>
    <time_frame>At the efficacy (scan) visit time point (12 weeks)</time_frame>
    <description>Patients' circulating tumor cell counts were obtained prior to and following therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Favorable LDH Count</measure>
    <time_frame>During treatment phase, then every 4 weeks until radiographic progression, assessed up to 6 months</time_frame>
    <description>Patient's LDH values were monitored prior to and following therapy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Disease Assessment With PSMA-Ligand Based Imaging Prior to and Following Investigational Treatment</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Patients underwent Gallium-68 PSMA PET prior to investigational therapy, and lesions were scored based on SUVmax</description>
  </other_outcome>
  <other_outcome>
    <measure>Radiation Dosimetry of Combination Therapy</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Patients underwent SPECT following administration of radionuclides</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>All Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>177Lu-PSMA-617 [1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration&#xD;
177Lu-J591 [1.35 GBq/m2 or 36.5 mCi/m2] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration&#xD;
68Ga-PSMA-HBED-CC [185 ±74 MBq or 5 ±2 mCi] intravenous during screening and at 12 weeks (±1 week) with standard imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-PSMA-617</intervention_name>
    <description>[1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)]</description>
    <arm_group_label>All Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-J591</intervention_name>
    <description>[1.35 GBq/m2 or 36.5 mCi/m2]</description>
    <arm_group_label>All Subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-PSMA-HBED-CC</intervention_name>
    <description>[185 ±74MBq or 5 ±2 mCi]</description>
    <arm_group_label>All Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Histologically or cytologically confirmed adenocarcinoma of prostate&#xD;
&#xD;
          2. Documented progressive metastatic CRPC based on Prostate Cancer Working Group 3&#xD;
             (PCWG3) criteria, which includes at least one of the following criteria:&#xD;
&#xD;
             i. PSA progression ii. Objective radiographic progression in soft tissue iii. New bone&#xD;
             lesions&#xD;
&#xD;
          3. ECOG performance status of 0-2&#xD;
&#xD;
          4. Have serum testosterone &lt; 50 ng/dL. Subjects must continue primary androgen&#xD;
             deprivation with an LHRH/GnRH analogue (agonist/antagonist) if they have not undergone&#xD;
             bilateral orchiectomy.&#xD;
&#xD;
          5. Have previously been treated with at least one of the following:&#xD;
&#xD;
               -  Androgen receptor signaling inhibitor (such as enzalutamide)&#xD;
&#xD;
               -  CYP 17 inhibitor (such as abiraterone acetate)&#xD;
&#xD;
          6. Have previously received taxane chemotherapy, been determined to be ineligible for&#xD;
             taxane chemotherapy by their physician, or refused taxane chemotherapy.&#xD;
&#xD;
          7. Age &gt; 18 years&#xD;
&#xD;
          8. Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Absolute neutrophil count &gt;2,000 cells/mm3&#xD;
&#xD;
               -  Hemoglobin ≥9 g/dL&#xD;
&#xD;
               -  Platelet count &gt;150,000 x 109/L&#xD;
&#xD;
               -  Serum creatinine &lt;1.5 x upper limit of normal (ULN) or calculated creatinine&#xD;
                  clearance ≥ 60 mL/min/1.73 m2 by Cockcroft-Gault&#xD;
&#xD;
               -  Serum total bilirubin&lt;1.5 x ULN (unless due to Gilbert's syndrome in which case&#xD;
                  direct bilirubin must be normal)&#xD;
&#xD;
               -  Serum AST and ALT&lt;1.5 x ULN in the absence of liver metastases; &lt;3 x ULN if due&#xD;
                  to liver metastases (in both circumstances bilirubin must meet entry criteria)&#xD;
&#xD;
          9. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Implantation of investigational medical device ≤4 weeks of Treatment visit #1 (Day 1)&#xD;
             or current enrollment in oncologic investigational drug or device study&#xD;
&#xD;
          2. Use of investigational drugs ≤4 weeks or &lt;5 half-lives of Treatment visit # 1(Day 1)&#xD;
             or current enrollment in investigational oncology drug or device study&#xD;
&#xD;
          3. Prior systemic beta-emitting bone-seeking radioisotopes&#xD;
&#xD;
          4. Known active brain metastases or leptomeningeal disease&#xD;
&#xD;
          5. History of deep vein thrombosis and/or pulmonary embolus within 1 month of Treatment&#xD;
             visit #1&#xD;
&#xD;
          6. Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or&#xD;
             hematological organ systems which might preclude completion of this study or interfere&#xD;
             with determination of causality of any adverse effects experienced in this study&#xD;
&#xD;
          7. Radiation therapy for treatment of PC ≤4 weeks of Treatment visit #1&#xD;
&#xD;
          8. Patients on stable dose of bisphosphonates or denosumab, which have been started no&#xD;
             less than 4 weeks prior to treatment start, may continue on this medication, however&#xD;
             patients are not allowed to initiate bisphosphonate/Denosumab therapy during the&#xD;
             DLT-assessment period of the study.&#xD;
&#xD;
          9. Having partners of childbearing potential and not willing to use a method of birth&#xD;
             control deemed acceptable by the principle investigator and chairperson during the&#xD;
             study and for 1 month after last study drug administration&#xD;
&#xD;
         10. Currently active other malignancy other than non-melanoma skin cancer. Patients are&#xD;
             considered not to have &quot;currently active&quot; malignancy if they have completed any&#xD;
             necessary therapy and are considered by their physician to be at less than 30% risk of&#xD;
             relapse.&#xD;
&#xD;
         11. Known history of known myelodysplastic syndrome&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Subjects who have documented progressive metastatic CRPC disease, who meet the inclusion and exclusion criteria will be eligible for participation in this study.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Tagawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <results_first_submitted>March 26, 2021</results_first_submitted>
  <results_first_submitted_qc>July 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2021</results_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
    <mesh_term>177Lu-PSMA-617</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03545165/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All 6 patients enrolled received both doses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Participants received two doses of 177Lu-J591 (60 mCi) + 177Lu-PSMA-617 (100 mCi), two weeks apart, with minimum 12 weeks of follow-up after last dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Participants received two doses of 177Lu-J591 (60 mCi) + 177Lu-PSMA-617 (100 mCi), two weeks apart, with minimum 12 weeks of follow-up after last dose.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" lower_limit="51" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate specific antigen (PSA)</title>
          <description>A tumor marker for prostate cancer (ng/mL)</description>
          <units>(ng/mL)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94" lower_limit="4.34" upper_limit="1398.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG score</title>
          <description>Eastern Cooperative Oncology Group (ECOG) score to assess performance status; the scale ranges from 0-4 with 0 corresponding to no functional limitations; a score of 1 indicates the patient has mild limitations and may be unable to engage in physically strenuous activities</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Halabi (CALGB) score</title>
          <description>Halabi (Cancer and Leukemia Group B [CALGB]) score to assess prognosis in patients with metastatic prostate cancer. Three categories include low, intermediate, and high risk.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Intermediate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone metastases</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Present</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lymph node metastases</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Present</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visceral metastases</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Present</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior androgen receptor pathway inhibitor</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Received</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did not receive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior chemotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Received</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Did not receive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Dose Limiting Toxicity (DLT) of Combination Therapy in a 2-Week Dose-Fractionation Regimen</title>
        <description>Dose limiting toxicity of combination therapy was determined by monitoring for adverse events following therapy</description>
        <time_frame>Approximately 3 months after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received two doses of 177Lu-J591 (60 mCi) + 177Lu-PSMA-617 (100 mCi), two weeks apart, with minimum 12 weeks of follow-up after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Dose Limiting Toxicity (DLT) of Combination Therapy in a 2-Week Dose-Fractionation Regimen</title>
          <description>Dose limiting toxicity of combination therapy was determined by monitoring for adverse events following therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RP2D) of Combination Therapy in a 2-Week Dose-Fractionation Regimen</title>
        <description>Cumulative maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of combination therapy was determined by monitoring dose-limiting toxicity and adverse events in the dosing or treatment cohorts</description>
        <time_frame>Approximately 3 months after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received two doses of 177Lu-J591 (60 mCi) + 177Lu-PSMA-617 (100 mCi), two weeks apart, with minimum 12 weeks of follow-up after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RP2D) of Combination Therapy in a 2-Week Dose-Fractionation Regimen</title>
          <description>Cumulative maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of combination therapy was determined by monitoring dose-limiting toxicity and adverse events in the dosing or treatment cohorts</description>
          <units>mCi</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Proportion With PSA Decline Following the Dose-Fractionated Combination Therapy by Comparing the Change in PSA Levels After Therapy to the Baseline, Pre-Treatment PSA.</title>
        <description>The proportion of patients with PSA decline following treatment with the combination of 177Lu-J591 and 177Lu-PSMA-617 was determined by comparing PSA levels prior to and following radionuclide therapy</description>
        <time_frame>At baseline and at 2 weeks on therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received two doses of 177Lu-J591 (60 mCi) + 177Lu-PSMA-617 (100 mCi), two weeks apart, with minimum 12 weeks of follow-up after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion With PSA Decline Following the Dose-Fractionated Combination Therapy by Comparing the Change in PSA Levels After Therapy to the Baseline, Pre-Treatment PSA.</title>
          <description>The proportion of patients with PSA decline following treatment with the combination of 177Lu-J591 and 177Lu-PSMA-617 was determined by comparing PSA levels prior to and following radionuclide therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Radiographic Response by RECIST 1.1 With Prostate Cancer Working Group 3 (PCWG3) Modifications</title>
        <description>Radiographic response rate was determined by scoring follow-up scans after therapy; RECIST 1.1 criteria with PCWG3 modifications were utilized</description>
        <time_frame>At the efficacy (scan) visit time point (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received two doses of 177Lu-J591 (60 mCi) + 177Lu-PSMA-617 (100 mCi), two weeks apart, with minimum 12 weeks of follow-up after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Radiographic Response by RECIST 1.1 With Prostate Cancer Working Group 3 (PCWG3) Modifications</title>
          <description>Radiographic response rate was determined by scoring follow-up scans after therapy; RECIST 1.1 criteria with PCWG3 modifications were utilized</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Progression-Free Survival by PCWG3 Criteria</title>
        <description>Biochemical progression-free survival was determined from date of first therapy to date of progression by PSA</description>
        <time_frame>Through study completion, up to 26 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received two doses of 177Lu-J591 (60 mCi) + 177Lu-PSMA-617 (100 mCi), two weeks apart, with minimum 12 weeks of follow-up after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Progression-Free Survival by PCWG3 Criteria</title>
          <description>Biochemical progression-free survival was determined from date of first therapy to date of progression by PSA</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiographic Progression-Free Survival by PCWG3 Criteria</title>
        <description>Radiographic progression-free survival was determined from date of first treatment to date of progression on follow-up imaging</description>
        <time_frame>Through study completion, up to 26 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received two doses of 177Lu-J591 (60 mCi) + 177Lu-PSMA-617 (100 mCi), two weeks apart, with minimum 12 weeks of follow-up after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Radiographic Progression-Free Survival by PCWG3 Criteria</title>
          <description>Radiographic progression-free survival was determined from date of first treatment to date of progression on follow-up imaging</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Following Treatment With the Combination of 177Lu-J591 and 177Lu-PSMA-617 in a 2-Week Dose-Fractionation Regimen</title>
        <description>Overall survival following treatment with the combination of 177Lu-J591 and 177Lu-PSMA-617 was determined from date of first treatment to date of death</description>
        <time_frame>Through study completion, up to 26 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received two doses of 177Lu-J591 (60 mCi) + 177Lu-PSMA-617 (100 mCi), two weeks apart, with minimum 12 weeks of follow-up after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Following Treatment With the Combination of 177Lu-J591 and 177Lu-PSMA-617 in a 2-Week Dose-Fractionation Regimen</title>
          <description>Overall survival following treatment with the combination of 177Lu-J591 and 177Lu-PSMA-617 was determined from date of first treatment to date of death</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="3" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in CTC Count as Measured by CellSearch</title>
        <description>Patients' circulating tumor cell counts were obtained prior to and following therapy</description>
        <time_frame>At the efficacy (scan) visit time point (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received two doses of 177Lu-J591 (60 mCi) + 177Lu-PSMA-617 (100 mCi), two weeks apart, with minimum 12 weeks of follow-up after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CTC Count as Measured by CellSearch</title>
          <description>Patients' circulating tumor cell counts were obtained prior to and following therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Decline</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Favorable CTC Count as Measured by Cell Search</title>
        <description>Patients' circulating tumor cell counts were obtained prior to and following therapy</description>
        <time_frame>At the efficacy (scan) visit time point (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received two doses of 177Lu-J591 (60 mCi) + 177Lu-PSMA-617 (100 mCi), two weeks apart, with minimum 12 weeks of follow-up after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Favorable CTC Count as Measured by Cell Search</title>
          <description>Patients' circulating tumor cell counts were obtained prior to and following therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Favorable LDH Count</title>
        <description>Patient's LDH values were monitored prior to and following therapy</description>
        <time_frame>During treatment phase, then every 4 weeks until radiographic progression, assessed up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received two doses of 177Lu-J591 (60 mCi) + 177Lu-PSMA-617 (100 mCi), two weeks apart, with minimum 12 weeks of follow-up after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Favorable LDH Count</title>
          <description>Patient's LDH values were monitored prior to and following therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Disease Assessment With PSMA-Ligand Based Imaging Prior to and Following Investigational Treatment</title>
        <description>Patients underwent Gallium-68 PSMA PET prior to investigational therapy, and lesions were scored based on SUVmax</description>
        <time_frame>Up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received two doses of 177Lu-J591 (60 mCi) + 177Lu-PSMA-617 (100 mCi), two weeks apart, with minimum 12 weeks of follow-up after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Assessment With PSMA-Ligand Based Imaging Prior to and Following Investigational Treatment</title>
          <description>Patients underwent Gallium-68 PSMA PET prior to investigational therapy, and lesions were scored based on SUVmax</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Highest lesion SUVmax &gt; 5x liver SUVmean</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Highest lesion SUVmax 2.5-5x liver SUVmean</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Highest lesion SUVmax 1-2.5x liver SUVmean</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Radiation Dosimetry of Combination Therapy</title>
        <description>Patients underwent SPECT following administration of radionuclides</description>
        <time_frame>Up to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Participants received two doses of 177Lu-J591 (60 mCi) + 177Lu-PSMA-617 (100 mCi), two weeks apart, with minimum 12 weeks of follow-up after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Radiation Dosimetry of Combination Therapy</title>
          <description>Patients underwent SPECT following administration of radionuclides</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tumor uptake at known sites of disease based on post-treatment planar imaging</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No tumor uptake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>minimum of 30 days following last dose of study drug, up to 26 months</time_frame>
      <desc>Adverse events were assessed and documented at each scheduled study visit and follow-up visit. Serious adverse events include death, life threatening adverse experiences, hospitalization or prolongation of hospitalization, disability or incapacitation, overdose, congenital anomalies and any other serious events that may jeopardize the subject or require medical or surgical intervention to prevent one of the outcomes listed in this definition.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>Participants received two doses of 177Lu-J591 (60 mCi) + 177Lu-PSMA-617 (100 mCi), two weeks apart, with minimum 12 weeks of follow-up after last dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <description>The patient experienced grade 3 dehydration from vomiting, requiring hospitalization for intravenous fluids. The event was not attributed to the study drug. The event was deemed unrelated. Patient's vomiting pre-dated enrollment on the study.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <description>The patient experienced grade 3 back pain, requiring hospitalization. The adverse event was not related to the study drug.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>xerostomia</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>transfusion reaction</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>blood bilirubin increased</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>creatinine increased</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>alkaline phosphatase increased</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>white blood cell decreased</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>white blood cell decreased</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>white blood cell decreased</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>lymphocyte count decreased</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>lymphocyte count decreased</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>platelet count decreased</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>platelet count decreased</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>platelet count decreased</sub_title>
                <description>grade 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>osteonecrosis of jaw</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>bone pain</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>peripheral motor neuropathy</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>hematuria</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>urinary tract obstruction</sub_title>
                <description>grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>bruising</sub_title>
                <description>grade 1-2</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated early due to sponsor withdrawal (PSMA-617 no longer available for purchase).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Scott Tagawa MD, Principal Investigator</name_or_title>
      <organization>Weill Cornell Medicine</organization>
      <phone>646-962-2072</phone>
      <email>guonc@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

